ADPT - Adaptive Biotechnologies Corp

ADPT - Adaptive Biotechnologies Corp

https://www.adaptivebiotech.com

Buy Momentum: Bearish

Recent News

Powered by Alpha Vantage

FDA Accepts Corcept's NDA for Relacorilant in Ovarian Cancer

Zacks Commentary • 3 days, 23 hours ago • score: 0.09

CORT's NDA for relacorilant in platinum-resistant ovarian cancer gains FDA acceptance, with a decision expected by July 2026.

IONS Up on FDA's Breakthrough Tag for ION582 in Angelman Syndrome

Zacks Commentary • 5 days ago • score: 0.09

Ionis jumps as FDA grants Breakthrough Therapy status to ION582 for treating Angelman syndrome, with the phase III study now underway.

Is Cardinal Health ( CAH ) Stock Outpacing Its Medical Peers This Year?

Zacks Commentary • 5 days, 2 hours ago • score: 0.16

Here is how Cardinal Health (CAH) and Adaptive Biotechnologies (ADPT) have performed compared to their sector so far this year.

AQST Stock Up as FDA Skips Advisory Meeting to Discuss Anaphylm NDA

Zacks Commentary • 1 week, 3 days ago • score: 0.09

Aquestive Therapeutics shares surge after FDA skips advisory meeting on Anaphylm NDA, keeping its January 2026 action date intact.

Sanofi Gets FDA Nod for Wayrilz in Immune Thrombocytopenia

Zacks Commentary • 1 week, 6 days ago • score: 0.08

SNY wins FDA approval for Wayrilz, the first BTK inhibitor for immune thrombocytopenia, with broader rare disease studies underway.

Are You Looking for a Top Momentum Pick? Why Adaptive Biotechnologies ( ADPT ) is a Great Choice

Zacks Commentary • 1 week, 6 days ago • score: 0.41

Does Adaptive Biotechnologies (ADPT) have what it takes to be a top stock pick for momentum investors? Let's find out.

Adaptive Biotechnologies Corporation ( ADPT ) Hits Fresh High: Is There Still Room to Run?

Zacks Commentary • 2 weeks, 3 days ago • score: 0.54

Adaptive Biotechnologies (ADPT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Is Adaptive Biotechnologies ( ADPT ) Outperforming Other Medical Stocks This Year?

Zacks Commentary • 3 weeks ago • score: 0.38

Here is how Adaptive Biotechnologies (ADPT) and Cardinal Health (CAH) have performed compared to their sector so far this year.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Range-Bound

As of 2025-09-10 (Snapshot)

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company is headquartered in Seattle, Washington.

52W High

$13.68

52W Low

$3.98

MA Status:

50D: Above 200D: Above

Beta (~1 neutral, <0.9 lower risk)

1.94

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-1.00

EV/Revenue (<3 favorable)

8.66

P/S (TTM) (<3 favorable)

9.22

P/B (<3 favorable)

10.52

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

2.34%

Institutions (25–75% balanced)

97.89%

Shares Outstanding

152,274,000

Float

117,370,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

205,216,000

Gross Profit (TTM)

125,706,000

EPS (TTM)

-0.81

Profit Margin (>10% good)

-0.59%

Operating Margin (TTM) (higher better)

-0.43%

ROE (TTM) (>15% strong)

-0.58%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

0.36

Momentum

Bearish momentum

Value

0.2752

Previous

0.3255

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025